XML 53 R8.htm IDEA: XBRL DOCUMENT

Business	3 Months Ended
Business	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	Business La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, the “Company”) is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA^TM (angiotensin II) was approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA U.S. net sales were $23.1 million in 2019 compared to $10.1 million in 2018, an increase of 129%. GIAPREZA U.S. net sales were $7.6 million for the three months ended March 31, 2020 compared to $4.4 million for the same period in 2019, an increase of 73%. In August 2019, GIAPREZA was approved by the European Commission (“EC”) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (I.V. artesunate) is La Jolla’s investigational product for the treatment of severe malaria. As of March 31, 2020 and December 31, 2019, the Company had cash of $77.2 million and $87.8 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”).